1-20 of 63
pharmacokinetics
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Meeting Abstracts

1650-P: Characterizing the Mechanism of Action of the Lipokine 12,13-diHOME

JARED I. SENFELD, MATTHEW LYNES, SEAN KODANI, KIN SING STEPHEN LEE, YU-HUA TSENG
Journal: Diabetes
Diabetes 2023;72(Supplement_1):1650-P
https://doi.org/10.2337/db23-1650-P
Published: 20 June 2023
View article titled, 1650-P: Characterizing the Mechanism of Action of the Lipokine 12,13-diHOME
Meeting Abstracts

769-P: Effect of Food on the Pharmacokinetics, Safety, and Tolerability of Orforglipron (LY3502970), an Oral, Nonpeptide GLP-1 Receptor Agonist

XIAOSU MA, RONG LIU, EDWARD J. PRATT, CHARLES BENSON, SHOBHA N. BHATTACHAR
Journal: Diabetes
Diabetes 2023;72(Supplement_1):769-P
https://doi.org/10.2337/db23-769-P
Published: 20 June 2023
View article titled, 769-P: Effect of Food on the Pharmacokinetics, Safety, and Tolerability of Orforglipron (LY3502970), an Oral, Nonpeptide GLP-1 Receptor Agonist
Meeting Abstracts

763-P: Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects—A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose (SAD and MAD) Study

KUN HE, FANG WEI, HONG CHEN, YANYAN ZHANG, ZHEN SHENG, QING WEN
Journal: Diabetes
Diabetes 2023;72(Supplement_1):763-P
https://doi.org/10.2337/db23-763-P
Published: 20 June 2023
View article titled, 763-P: Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects—A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose (SAD and MAD) Study
Meeting Abstracts

808-P: Pharmacokinetic Properties of Once-Weekly Insulin Icodec in Individuals with Renal Impairment vs. Normal Renal Function

HANNE HAAHR, NIELS R. KRISTENSEN, JONAS H. LARSEN, FRANK-DIETRICH H. WAGNER, STANISLAV IGNATENKO
Journal: Diabetes
Diabetes 2023;72(Supplement_1):808-P
https://doi.org/10.2337/db23-808-P
Published: 20 June 2023
View article titled, 808-P: Pharmacokinetic Properties of Once-Weekly Insulin Icodec in Individuals with Renal Impairment vs. Normal Renal Function
Meeting Abstracts

95-LB: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Small Molecule GLP-1 Receptor Agonist (HRS-7535) in Healthy Subjects —A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study

JINGYING WU, WEI HU, YIJUN DU, QIAN ZHANG, RENPENG ZHOU, QIN ZHANG, HUILING QIN, ZI YE, YIMEI XU, SHENG FENG, CHANG SHU, YU SHEN, YANG FAN
Journal: Diabetes
Diabetes 2023;72(Supplement_1):95-LB
https://doi.org/10.2337/db23-95-LB
Published: 20 June 2023
View article titled, 95-LB: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Small Molecule GLP-1 Receptor Agonist (HRS-7535) in Healthy Subjects —A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study
Meeting Abstracts

80-LB: Evaluation of the Pharmacokinetics of Glucagon-Like-Peptide-1 (GLP-1) Receptor Agonist Delivered through the BIOJET Oral Biotherapeutic Delivery Platform in Porcine Model

SHAOYING N. LEE, CHERYL A. STORK, RENE O. VALENZUELA-RIVAS, MICHELLE WALKER, BRYAN J. SMITH, JEFFREY A. SMITH, NELSON QUINTANA, CHRIS WAHL, SHARAT SINGH
Journal: Diabetes
Diabetes 2023;72(Supplement_1):80-LB
https://doi.org/10.2337/db23-80-LB
Published: 20 June 2023
View article titled, 80-LB: Evaluation of the Pharmacokinetics of Glucagon-Like-Peptide-1 (GLP-1) Receptor Agonist Delivered through the BIOJET Oral Biotherapeutic Delivery Platform in Porcine Model
Meeting Abstracts

336-OR: A First-in-Human Single- and Multiple-Ascending Dose Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Nonpeptide GLP-1 Receptor Agonist in Healthy Subjects

EDWARD J. PRATT, XIAOSU MA, RONG LIU, DEBORAH A. ROBINS, KYLE SLOOP, CHARLES BENSON
Journal: Diabetes
Diabetes 2022;71(Supplement_1):336-OR
https://doi.org/10.2337/db22-336-OR
Published: 01 June 2022
View article titled, 336-OR: A First-in-Human Single- and Multiple-Ascending Dose Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Nonpeptide GLP-1 Receptor Agonist in Healthy Subjects
Meeting Abstracts

93-LB: A Randomized Clinical Trial of Safety, Pharmacokinetics, and Pharmacodynamics of Weekly Dosing Supagutide in Healthy Chinese Subjects

ANRAN MA, YUE ZHOU, YAN-RU LOU, YIJING LIAO, ANNA SHAO, ZHIHONG WANG, YAOJING JIANG, QIAOLI CUI, YING ZHAO, JIA LI, GERALD J. PRUD’HOMME, DALONG ZHU, QINGHUA WANG
Journal: Diabetes
Diabetes 2022;71(Supplement_1):93-LB
https://doi.org/10.2337/db22-93-LB
Published: 01 June 2022
View article titled, 93-LB: A Randomized Clinical Trial of Safety, Pharmacokinetics, and Pharmacodynamics of Weekly Dosing Supagutide in Healthy Chinese Subjects
Meeting Abstracts

742-P: Antidrug Antibodies Do Not Impact Pharmacokinetics, Efficacy, and Safety of Tirzepatide: Analysis of Data from 7 Phase 3 Studies

BORIS CALDERON, GARRETT R. MULLINS, MICHAEL HODSDON, GRACE LI, GREG ANGLIN, SHWETA URVA, KAREN SCHNECK, JENNIFER N. BARDOS, RICARDO F. MARTINS, KATELYN BROWN
Journal: Diabetes
Diabetes 2022;71(Supplement_1):742-P
https://doi.org/10.2337/db22-742-P
Published: 01 June 2022
View article titled, 742-P: Antidrug Antibodies Do Not Impact Pharmacokinetics, Efficacy, and Safety of Tirzepatide: Analysis of Data from 7 Phase 3 Studies
Meeting Abstracts

802-P: Safety, Pharmacokinetics, and Pharmacodynamics of Once-Weekly Basal Insulin Fc (BIF) in Japanese Patients with Type 2 Diabetes: A Phase 1 Open-Label, Randomized, Active-Controlled Trial

RISA NASU, TOMONORI OURA, KENJI OHWAKI, MAKOTO IMORI, KENICHI FURIHATA
Journal: Diabetes
Diabetes 2022;71(Supplement_1):802-P
https://doi.org/10.2337/db22-802-P
Published: 01 June 2022
View article titled, 802-P: Safety, Pharmacokinetics, and Pharmacodynamics of Once-Weekly Basal Insulin Fc (BIF) in Japanese Patients with Type 2 Diabetes: A Phase 1 Open-Label, Randomized, Active-Controlled Trial
Meeting Abstracts

765-P: DA-1241, a Novel GPR119 Agonist: Data on Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) from Part 2 of a Phase 1b Multiple Ascending Dose (MAD) Study in Patients with Type 2 Diabetes Mellitus (T2DM)

MI-KYUNG KIM, DAE YOUNG LEE, JIYOON JEONG, MICHAEL GRIMM, BRIDGETTE B. FRANEY, MARCUS HOMPESCH
Journal: Diabetes
Diabetes 2021;70(Supplement_1):765-P
https://doi.org/10.2337/db21-765-P
Published: 01 June 2021
View article titled, 765-P: DA-1241, a Novel GPR119 Agonist: Data on Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) from Part 2 of a Phase 1b Multiple Ascending Dose (MAD) Study in Patients with Type 2 Diabetes Mellitus (T2DM)
Meeting Abstracts

766-P: DA-1241, a Novel GPR119 Agonist: Data on Safety, Tolerability, and Pharmacokinetics (PK) from Part 1 of a Phase 1b Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HV)

MI-KYUNG KIM, DAE YOUNG LEE, JIYOON JEONG, MICHAEL GRIMM, BRIDGETTE B. FRANEY, MARCUS HOMPESCH
Journal: Diabetes
Diabetes 2021;70(Supplement_1):766-P
https://doi.org/10.2337/db21-766-P
Published: 01 June 2021
View article titled, 766-P: DA-1241, a Novel GPR119 Agonist: Data on Safety, Tolerability, and Pharmacokinetics (PK) from Part 1 of a Phase 1b Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HV)
Meeting Abstracts

688-P: Effect of Probenecid and Cyclosporin on the Pharmacokinetics of SNAC in Healthy Subjects

TANJA K. THORNING, ASTRID BREITSCHAFT, THOMAS BO JENSEN, KLAUS KALLENBACH, TINE A. BÆKDAL
Journal: Diabetes
Diabetes 2021;70(Supplement_1):688-P
https://doi.org/10.2337/db21-688-P
Published: 01 June 2021
View article titled, 688-P: Effect of Probenecid and Cyclosporin on the Pharmacokinetics of SNAC in Healthy Subjects
Meeting Abstracts

239-OR: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Four-Period, Crossover Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Three Dose Levels of PB201 as Monotherapy in Subjects with Type 2 Diabetes Mellitus

MIN XU, GROUP PEGBIO STUDY
Journal: Diabetes
Diabetes 2021;70(Supplement_1):239-OR
https://doi.org/10.2337/db21-239-OR
Published: 01 June 2021
View article titled, 239-OR: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Four-Period, Crossover Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Three Dose Levels of PB201 as Monotherapy in Subjects with Type 2 Diabetes Mellitus
Meeting Abstracts

79-LB: Pharmacokinetics and Pharmacodynamics of Avexitide (Exendin 9-39) in Neonates and Infants with Congenital Hyperinsulinism

COLLEEN CRAIG, DIVA D. DE LEON
Journal: Diabetes
Diabetes 2021;70(Supplement_1):79-LB
https://doi.org/10.2337/db21-79-LB
Published: 01 June 2021
View article titled, 79-LB: Pharmacokinetics and Pharmacodynamics of Avexitide (Exendin 9-39) in Neonates and Infants with Congenital Hyperinsulinism
Meeting Abstracts

352-OR: Combination Therapy with Dapagliflozin plus Exenatide on Endogenous Glucose Production: A Mechanism of Action Study

MARIAM ALATRACH, CHRISTINA AGYIN, IV, JOHN M. ADAMS, II, OLGA LAVRYNENKO, NITCHAKARN LAICHUTHAI, EUGENIO CERSOSIMO, CURTIS L. TRIPLITT, AMALIA GASTALDELLI, MUHAMMAD ABDUL-GHANI, RALPH A. DEFRONZO
Journal: Diabetes
Diabetes 2020;69(Supplement_1):352-OR
https://doi.org/10.2337/db20-352-OR
Published: 01 June 2020
View article titled, 352-OR: Combination Therapy with Dapagliflozin plus Exenatide on Endogenous Glucose Production: A Mechanism of Action Study
Meeting Abstracts

971-P: Renal Impairment Has No Impact on the Clinical Pharmacokinetics of Tirzepatide

SHWETA URVA, TONYA QUINLAN, JOHN LANDRY, JENNIFER MARTIN, CORINA LOGHIN
Journal: Diabetes
Diabetes 2020;69(Supplement_1):971-P
https://doi.org/10.2337/db20-971-P
Published: 01 June 2020
View article titled, 971-P: Renal Impairment Has No Impact on the Clinical Pharmacokinetics of Tirzepatide
Meeting Abstracts

941-P: A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Semaglutide in Healthy Chinese Subjects

AIXIN SHI, PANPAN XIE, LASSE L. NIELSEN, TRINE V. SKJOETH, XUEMEI HE, SINE P. HAUGAARD
Journal: Diabetes
Diabetes 2020;69(Supplement_1):941-P
https://doi.org/10.2337/db20-941-P
Published: 01 June 2020
View article titled, 941-P: A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Semaglutide in Healthy Chinese Subjects
Meeting Abstracts

948-P: A Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15136, a Novel Long-Acting Glucagon Analogue, in Healthy Subjects

KI YOUNG HUH, WONJUNG SHIN, EUNHYE BAEK, SUJIN SEO, WOOSUN LEE, SEUNGJAE BAEK, HOWARD LEE
Journal: Diabetes
Diabetes 2020;69(Supplement_1):948-P
https://doi.org/10.2337/db20-948-P
Published: 01 June 2020
View article titled, 948-P: A Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15136, a Novel Long-Acting Glucagon Analogue, in Healthy Subjects
Meeting Abstracts

107-LB: Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Healthy Subjects (HS)

LINDA MORROW, MICHAEL GRIMM, CARINE BEYSEN, GEOFFREY WALFORD, KELLY DUNCAN, PRANAB K. MITRA, PAVAN VADDADY, MARCUS HOMPESCH
Journal: Diabetes
Diabetes 2020;69(Supplement_1):107-LB
https://doi.org/10.2337/db20-107-LB
Published: 01 June 2020
View article titled, 107-LB: Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Healthy Subjects (HS)